Atomo Diagnostics receives major grant

Atomo Diagnostics (ASX:AT1) has been awarded a $2.44 million grant from the Cooperative Research Centres Projects (CRC-P) of the Australian Department of Industry, Science and Resources. This funding will support the development of a groundbreaking rapid test for detecting active syphilis infections. The project is a collaboration with the Burnet Institute and IDE Group, focusing on creating a test for both professional and at-home use.

Summary of Atomo Diagnostics' announcement

Atomo Diagnostics has announced the receipt of a $2.44 million grant to develop a rapid syphilis test that distinguishes active from previously treated infections. This project, in collaboration with the Burnet Institute and IDE Group, aims to address the rising global syphilis rates. Atomo will use its Pascal cassette technology, offering a test for both clinical and self-testing environments. The company aims to expand its market presence, building on the success of its HIV Self-Test. Atomo's focus remains on providing innovative solutions for public health challenges, leveraging commercial channels to make the test widely available.

Insights from Atomo Diagnostics

We are excited to leverage our expertise in rapid diagnostics and work alongside our partners to address a significant public health challenge. This test will provide an important tool in the fight against syphilis, which is seeing increasing rates globally. By utilizing Atomo's proven technology, we aim to deliver a product that will be both accessible and reliable for consumers worldwide.